| |||
| |||
| |||
| |||
| |||
| |||
Clive Maund, CliveMaund.com(7/14/20) |
|||
|
|||
Cosme Ordonez, Noble Capital Markets(4/20/20) |
|||
|
Clive Maund – CliveMaund.com |
The information provided above is from analysts, newsletters, the company and other contributors.
ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.
The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.
The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.
Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
Readers should conduct their own research for all information publicly available concerning the company.
Unique tech. platform creates highly selective antibodies for root cause of Alzheimer’s, ALS and Parkinson’s | |
2nd generation PMN 310, anticipated to show significant advantages in efficacy & safety vs Biogen’s 1st to market aducanumab in Alzheimer’s | |
Unique platform supports development of highly sensitive & specific blood test for antibodies specific for COVID-19 |
![]() Q2 2020 |
Potential successful serological antibody test for COVID-19 (end June 2020); expansion of current co
|
![]() Q2 2020 |
Potential collaborations with pharma partners/patient associations forALS, Parkinson’s disease (comi
|
![]() Q3 2020 |
Anticipated approval of Biogen’s aducanumab for AD, rolling BLA ongoing, news expected around end Q3
|